Key Points
- Julie Rubinstein, Adaptive Biotechnologies' COO, executed repeated insider sales (totaling about 344,064 shares) over March–April, including a 19,060-share sale on April 10; the trades were carried out under a pre-arranged Rule 10b5-1 plan.
- Following the April 10 transaction she directly owns 425,512 shares (valued at about $5.43 million), which the filing reports as a 4.29% reduction in her ownership from before the sale.
- Adaptive recently beat quarterly EPS and revenue expectations (revenue $71.7M vs. $59.4M est., up ~51% year-over-year), and analysts maintain a generally positive view with an average price target of about $18.25 ("Moderate Buy").
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company's stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $12.77, for a total value of $243,396.20. Following the transaction, the chief operating officer directly owned 425,512 shares of the company's stock, valued at $5,433,788.24. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total value of $250,639.00.
- On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
- On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
- On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total value of $254,832.20.
- On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.
- On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
Adaptive Biotechnologies Stock Performance
Shares of NASDAQ ADPT opened at $14.13 on Tuesday. The stock has a 50 day moving average price of $14.87 and a 200 day moving average price of $15.99. Adaptive Biotechnologies Corporation has a 52 week low of $6.77 and a 52 week high of $20.76. The stock has a market capitalization of $2.18 billion, a PE ratio of -35.32 and a beta of 2.29.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. During the same period in the prior year, the firm posted ($0.23) earnings per share. The business's quarterly revenue was up 51.0% compared to the same quarter last year. As a group, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Hedge Funds Weigh In On Adaptive Biotechnologies
A number of hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in Adaptive Biotechnologies by 3.1% during the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock worth $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC increased its stake in Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock worth $641,000 after acquiring an additional 904 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Adaptive Biotechnologies by 3.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company's stock worth $355,000 after acquiring an additional 910 shares during the period. California State Teachers Retirement System increased its stake in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock worth $1,145,000 after acquiring an additional 933 shares during the period. Finally, Captrust Financial Advisors increased its stake in Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock worth $184,000 after acquiring an additional 1,119 shares during the period. Institutional investors own 99.17% of the company's stock.
Analysts Set New Price Targets
Several research analysts recently commented on ADPT shares. Guggenheim increased their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research report on Friday, February 6th. BTIG Research raised their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. raised their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $18.25.
Check Out Our Latest Stock Analysis on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
